drugset / Trial / NCT03384823

A Study of EDP-938 in Healthy Subjects

NCT03384823

RandomizedParallel-groupTriple-blindTreatment

Summary

This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-938 in healthy adult subjects

Timeline

Start
2017-12-07
Primary completion
2018-07-03
Completion
2018-07-03

Drugs

EvaluationDrugModalityDoseRoute
Subject zelicapavir Small molecule Oral